This page uses content from Wikipedia and is licensed under CC BY-SA.

Galcanezumab

Galcanezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCALCA, CALCB
Clinical data
Trade namesEmgality
Other namesLY2951742
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9854N1686O2018S46
Molar mass144083.69 g·mol−1

Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[1][2] It is also used for cluster headaches.[3]

Common side effects include pain or redness at the site of injection.[3] Other side effects may include hypersensitivity reactions.[3] It is directed against calcitonin-related polypeptides alpha and beta.

This drug was developed by Eli Lilly.[4] It was approved for medical use in the United States in 2018, becoming the third CGRP inhibitor to do so.[5] When used for migraines it costs about 7,000 USD per year in the United States as of 2019.[6]

See also

References

  1. ^ "Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ^ a b c "FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks". FDA. 4 June 2019. Retrieved 6 June 2019.
  4. ^ H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
  5. ^ "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.
  6. ^ "FDA approves Lilly's migraine drug as first ever cluster headache treatment". CNBC. 4 June 2019. Retrieved 6 June 2019.